Cargando…

The seroprevalence of human papillomavirus by immune status and by ethnicity in London

BACKGROUND: The natural history of cutaneous HPV is unclear and in particular, seroprevalence among individuals with different levels of immune function and ethnicity is unknown. As part of a study of cutaneous squamous cell carcinoma (SCC) and HPV among organ transplant recipients (OTR) from London...

Descripción completa

Detalles Bibliográficos
Autores principales: Casabonne, Delphine, Waterboer, Tim, Michael, Kristina M, Pawlita, Michael, Mitchell, Liza, Newton, Robert, Harwood, Catherine, Proby, Charlotte
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760503/
https://www.ncbi.nlm.nih.gov/pubmed/19751501
http://dx.doi.org/10.1186/1750-9378-4-14
_version_ 1782172745006579712
author Casabonne, Delphine
Waterboer, Tim
Michael, Kristina M
Pawlita, Michael
Mitchell, Liza
Newton, Robert
Harwood, Catherine
Proby, Charlotte
author_facet Casabonne, Delphine
Waterboer, Tim
Michael, Kristina M
Pawlita, Michael
Mitchell, Liza
Newton, Robert
Harwood, Catherine
Proby, Charlotte
author_sort Casabonne, Delphine
collection PubMed
description BACKGROUND: The natural history of cutaneous HPV is unclear and in particular, seroprevalence among individuals with different levels of immune function and ethnicity is unknown. As part of a study of cutaneous squamous cell carcinoma (SCC) and HPV among organ transplant recipients (OTR) from London, we investigated the seroprevalence and risk factors for 34 HPV types (detected using Luminex technology) among 409 OTR patients without skin cancer (243 Caucasians and 166 non-Caucasians), 367 individuals with end stage renal failure on dialysis (222 Caucasians and 145 non-Caucasians) and 152 immunocompetent (IC) individuals without skin cancer (102 Caucasians and 50 non-Caucasians) to compare the HPV seroprevalence in patients with differing immune status and ethnicity. In total, seroprevalence data from 928 individuals, all from London, was available. RESULTS: Overall, no difference between HPV seroprevalence by immune status was observed (P = 0.3) among Caucasian or among non-Caucasian individuals, with seroprevalence varying from 87% to 94% across different immune status and ethnic groups. Those individuals seropositive to multiple types of one genus were more likely to be seroreactive to multiple types of another genus, independent of immune status or ethnicity. Lower seroprevalence for gammaHPV 4, and to a lesser extent gammaHPV 48, were observed among OTR compared to IC and dialysis patients. Higher seroprevalence against antibodies to betaHPV 93 were detected more frequently in non-Caucasians than Caucasians whereas muHPV 1 and, to a lesser extent, gammaHPV 4 were found more frequently among Caucasians - these findings were independent of immune status. Within non-Caucasian subgroups, the seroprevalence of 8 HPV (alpha-mucosal HPV16 and 13, alpha-cutaneous HPV7 and 2, betaHPV8, 17, 23 and 38) was significantly (P < 0.02) higher in Black compared to Asian patients. HPV16 being sexually transmitted, this might suggest a potential sexual route of transmission for some beta HPV types. CONCLUSION: We did not observe major disturbance in antibody response between immunocompetent, dialysis and OTR individuals, but significant differences in HPV seroprevalence were identified according to ethnicity. Further research is needed to clarify the natural history of cutaneous HPV, particularly given the growing research interest in its possible role in the pathogenesis of cutaneous SCC.
format Text
id pubmed-2760503
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27605032009-10-13 The seroprevalence of human papillomavirus by immune status and by ethnicity in London Casabonne, Delphine Waterboer, Tim Michael, Kristina M Pawlita, Michael Mitchell, Liza Newton, Robert Harwood, Catherine Proby, Charlotte Infect Agent Cancer Research Article BACKGROUND: The natural history of cutaneous HPV is unclear and in particular, seroprevalence among individuals with different levels of immune function and ethnicity is unknown. As part of a study of cutaneous squamous cell carcinoma (SCC) and HPV among organ transplant recipients (OTR) from London, we investigated the seroprevalence and risk factors for 34 HPV types (detected using Luminex technology) among 409 OTR patients without skin cancer (243 Caucasians and 166 non-Caucasians), 367 individuals with end stage renal failure on dialysis (222 Caucasians and 145 non-Caucasians) and 152 immunocompetent (IC) individuals without skin cancer (102 Caucasians and 50 non-Caucasians) to compare the HPV seroprevalence in patients with differing immune status and ethnicity. In total, seroprevalence data from 928 individuals, all from London, was available. RESULTS: Overall, no difference between HPV seroprevalence by immune status was observed (P = 0.3) among Caucasian or among non-Caucasian individuals, with seroprevalence varying from 87% to 94% across different immune status and ethnic groups. Those individuals seropositive to multiple types of one genus were more likely to be seroreactive to multiple types of another genus, independent of immune status or ethnicity. Lower seroprevalence for gammaHPV 4, and to a lesser extent gammaHPV 48, were observed among OTR compared to IC and dialysis patients. Higher seroprevalence against antibodies to betaHPV 93 were detected more frequently in non-Caucasians than Caucasians whereas muHPV 1 and, to a lesser extent, gammaHPV 4 were found more frequently among Caucasians - these findings were independent of immune status. Within non-Caucasian subgroups, the seroprevalence of 8 HPV (alpha-mucosal HPV16 and 13, alpha-cutaneous HPV7 and 2, betaHPV8, 17, 23 and 38) was significantly (P < 0.02) higher in Black compared to Asian patients. HPV16 being sexually transmitted, this might suggest a potential sexual route of transmission for some beta HPV types. CONCLUSION: We did not observe major disturbance in antibody response between immunocompetent, dialysis and OTR individuals, but significant differences in HPV seroprevalence were identified according to ethnicity. Further research is needed to clarify the natural history of cutaneous HPV, particularly given the growing research interest in its possible role in the pathogenesis of cutaneous SCC. BioMed Central 2009-09-14 /pmc/articles/PMC2760503/ /pubmed/19751501 http://dx.doi.org/10.1186/1750-9378-4-14 Text en Copyright © 2009 Casabonne et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Casabonne, Delphine
Waterboer, Tim
Michael, Kristina M
Pawlita, Michael
Mitchell, Liza
Newton, Robert
Harwood, Catherine
Proby, Charlotte
The seroprevalence of human papillomavirus by immune status and by ethnicity in London
title The seroprevalence of human papillomavirus by immune status and by ethnicity in London
title_full The seroprevalence of human papillomavirus by immune status and by ethnicity in London
title_fullStr The seroprevalence of human papillomavirus by immune status and by ethnicity in London
title_full_unstemmed The seroprevalence of human papillomavirus by immune status and by ethnicity in London
title_short The seroprevalence of human papillomavirus by immune status and by ethnicity in London
title_sort seroprevalence of human papillomavirus by immune status and by ethnicity in london
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760503/
https://www.ncbi.nlm.nih.gov/pubmed/19751501
http://dx.doi.org/10.1186/1750-9378-4-14
work_keys_str_mv AT casabonnedelphine theseroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT waterboertim theseroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT michaelkristinam theseroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT pawlitamichael theseroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT mitchellliza theseroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT newtonrobert theseroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT harwoodcatherine theseroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT probycharlotte theseroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT casabonnedelphine seroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT waterboertim seroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT michaelkristinam seroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT pawlitamichael seroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT mitchellliza seroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT newtonrobert seroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT harwoodcatherine seroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon
AT probycharlotte seroprevalenceofhumanpapillomavirusbyimmunestatusandbyethnicityinlondon